Product-Specific Guidances; Revised Draft Guidances for Industry; Availability
FDA released revised draft product-specific guidances for industry, providing updated recommendations on drug development and bioequivalence studies.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 29, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing facilities (503B). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comments on the draft guidances are due by September 28, 2026 (60 days after publication on July 29, 2026).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA published revised draft product-specific guidances with updated recommendations for specific drug products.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing facilities (503B).
What you must do
Review the revised draft guidances for products in your pipeline and assess impact on development plans.
Deadline
Comments on the draft guidances are due by September 28, 2026 (60 days after publication on July 29, 2026).
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trial